Recursion Pharmaceuticals Reports Q3 2026 Revenue Growth and Clinical Progress
Recursion Pharmaceuticals (RXRX) reported third-quarter revenue of $18.6 million, a significant increase from $5.2 million in the prior year, driven largely by milestone payments from strategic collaboration partners. While the company recorded a net loss of $119 million for the quarter, this represents an improvement over the $162.3 million loss reported during the same period in 2025. The company maintains a strong liquidity position with approximately $748.7 million in pro forma cash following an oversubscribed October financing round. Clinical updates highlighted positive data for REC-4881, showing high polyp reduction rates and durability in the TUPELO study, as well as promising disease control rates for REC-1245 in the DAHLIA study. Management emphasized operational discipline, projecting cash operating expenses to remain below $375 million for 2026 and $360 million for 2027. The company continues to leverage its AI-driven platform to achieve higher molecular design efficiency and faster clinical enrollment compared to industry benchmarks.
Tickers: $RXRX
Topics: Biotechnology Cash Runway Clinical Trial Results Net Loss Revenue Growth